MediWound’s NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters

YAVNE, Israel, Jan. 11, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that two presentations highlighting NexoBrid’s potential role in managing Mass Casualty Incidence will be presented at the 4th International Conference on Preparedness and Response of Healthcare Systems to Emergencies and Disasters (IPRED IV), being held January 10 – 13, 2016 in Tel Aviv.

The following presentations highlighting NexoBrid will be presented on January 12th between 14:40-16:10:

Title:“The Role of Effective, Fast and Specific Enzymatic Debriding Agent”
Authors: Prof. Lior Rosenberg, M.D., Chief Medical and Technology Officer, MediWound Ltd.
Title:“The role of NexoBrid rapid enzymatic debridement in the treatment of fire disasters in view of the recent Romanian mass casualty incident”
Authors:Yaron Shoham, M.D., Director of Medical Affairs, MediWound Ltd.

The Israeli Ministry of Health and the Home Front Command have established a tradition of providing an international platform for sharing ideas, knowledge and experience for practitioners and researchers in the fields of preparedness and response to disasters and emergencies.

The IPRED IV conference will provide an excellent platform and opportunity for international networking, as well as enhancement of research, in order to contribute towards the development of the Science of Emergency Preparedness and Response.

MediWound is currently conducting a U.S. Phase 3 clinical study of NexoBrid for the removal of eschar in adults with deep-partial and full-thickness thermal burns, which is being funded, in part, with federal funds under a contract from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) that is valued at up to $112 million. The BARDA contract underscores the important role NexoBrid can have in treating severe burn patients, particularly in mass casualty incidents, where rapid medical intervention is critical.

“The use of NexoBrid, a fast-acting, eschar-specific enzymatic debriding agent, reduces surgical burden and can contribute in a mass casualty incidence by reducing dependency on burn specialists, nurses and surgical facilities, which are scarce during such large scale emergencies. The resulting reduced surgical burden may increase surge capacity and preparedness for burn mass casualties disasters,” said Gal Cohen, President and Chief Executive Officer of MediWound.

“In a disaster in Romania, where the capacity to carry out surgeries in over 100 burn victims was limited, NexoBrid demonstrated its ability to contribute to the management of a mass casualty incidence by allowing for the nonsurgical treatment of over 35 patients in less than three days, thus alleviating the surgical bottleneck,” noted Mr. Cohen.

“We look forward to working with various governments and international agencies to advance the use of NexoBrid for mass casualty and disaster preparedness, as well as in military medicine,” added Mr. Cohen.

About NexoBrid
NexoBrid represents a new paradigm in burn care management having demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove in a single, four-hour application the dead or the damaged tissue (eschar) earlier than other modalities, without harming viable tissue. In clinical studies NexoBrid has demonstrated a significant reduction in surgical burden with long-term outcomes that are comparable to the current surgical treatment. NexoBrid was granted marketing authorization from the European Medicines Agency and the Israeli and Argentinean Ministries of Health for the removal of eschar in adults with deep partial and full-thickness thermal burns, and has been launched in Europe and Israel.

About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns and has been launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to commercial results, clinical trials and the regulatory authorizations. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2014 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Anne Marie Fields
Sharon MalkaSenior Vice President
Chief Financial & Operations Officer LHA
MediWound Ltd.212-838-3777

Source:MediWound Ltd.